Chinese and American researchers found that the combination of diphosphonic acid and rapamycin can treat drug-resistant lung cancer

Chinese and American researchers said Tuesday they have found a promising treatment for drug-resistant lung cancer The results showed that the survival time of mice with cancer could be doubled by using rapamycin, a drug for osteoporosis and an immunomodulatory drug The study, published in the US journal of Science Translational Medicine, was aimed at lung cancer with mutations in the KRAS gene KRAS mutation is a common gene mutation, which can be seen in 20% to 30% of lung adenocarcinoma (a common lung cancer), 40% of colorectal cancer and more than 90% of pancreatic cancer It often leads to drug resistance of cancer Therefore, when some cancer drugs are used in clinic, it is required to detect KRAS mutation in patients first In the mouse experiment, Zhang Yonghui, Professor of Tsinghua University and Dr Xia Yifeng of Salk Institute of biology in the United States, as well as colleagues of the University of Illinois, adopted the strategy of combination of diphosphonic acid and rapamycin to treat KRAS mutant lung adenocarcinoma Zhang Yonghui said that the two kinds of drugs have a strong synergistic effect in the body, and will work together to kill the cancer cells mutated by KRAS In the experiment of mice, the tumor reduced greatly, and the survival time of mice increased from 28 days to 54 days, nearly doubling Zhang Yonghui stressed that this work does not show that they have found a final solution to the KRAS mutation, and whether it can ultimately benefit patients, but also depends on the results of clinical trials.